Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
54.25
+0.70 (1.31%)
At close: Jun 6, 2025, 4:00 PM
54.49
+0.24 (0.44%)
After-hours: Jun 6, 2025, 7:48 PM EDT
Halozyme Therapeutics Stock Forecast
Stock Price Forecast
According to 9 professional analysts, the 12-month price target for Halozyme Therapeutics stock ranges from a low of $49 to a high of $75. The average analyst price target of $63.56 forecasts a 17.16% increase in the stock price over the next year.
Price Target: $63.56 (+17.16%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Halozyme Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Hold | 4 | 4 | 4 | 4 | 4 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $72 | Strong Buy | Reiterates | $72 | +32.72% | May 29, 2025 |
| Morgan Stanley | Morgan Stanley | Buy → Hold Downgrades $73 → $62 | Buy → Hold | Downgrades | $73 → $62 | +14.29% | May 14, 2025 |
| Wells Fargo | Wells Fargo | Hold Maintains $60 → $65 | Hold | Maintains | $60 → $65 | +19.82% | May 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $72 | Strong Buy | Reiterates | $72 | +32.72% | Apr 25, 2025 |
| JP Morgan | JP Morgan | Hold Maintains $55 → $58 | Hold | Maintains | $55 → $58 | +6.91% | Apr 21, 2025 |
Financial Forecast
Revenue This Year
1.28B
from 1.02B
Increased by 25.77%
Revenue Next Year
1.51B
from 1.28B
Increased by 18.01%
EPS This Year
5.33
from 3.43
Increased by 55.41%
EPS Next Year
7.00
from 5.33
Increased by 31.36%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.4B | 1.7B | 1.9B | ||
| Avg | 1.3B | 1.5B | 1.7B | ||
| Low | 1.2B | 1.2B | 1.3B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 33.4% | 30.8% | 29.0% | ||
| Avg | 25.8% | 18.0% | 13.8% | ||
| Low | 19.1% | -6.4% | -12.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 5.91 | 8.03 | 9.98 | ||
| Avg | 5.33 | 7.00 | 8.61 | ||
| Low | 4.05 | 5.55 | 6.71 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 72.3% | 50.7% | 42.5% | ||
| Avg | 55.4% | 31.4% | 22.9% | ||
| Low | 18.0% | 4.1% | -4.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.